Targeted metabolomics reveals tricarboxylic acid cycle-related metabolites serve as predictive biomarkers for trastuzumab resistance in human epidermal growth factor receptor 2-positive breast cancer
{{output}}
Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2), has been proven to be effective in enhancing overall survival in patients with HER2-positive breast cancer. However, some patients exhibit resistance to trastuzumab-bas... ...
